Related Experiment Video
Updated: Mar 24, 2026

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
Published on: August 20, 2019
The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling
1Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; DZHK (German Centre for Cardiovascular Research) partner site RhineMain, Germany.
Abstract:
Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to generate epoxyeicosatrienoic acids (EETs). The latter are biologically active and reported to act as an endothelium-derived hyperpolarizing factor (EDHF) as well as to affect angiogenic and inflammatory signaling pathways. In addition to arachidonic acid, the CYP epoxygenases also metabolize the Ω-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid and docosahexaenoic acid, to generate bioactive lipid epoxide mediators. The latter can be more potent than the EETs but their actions are under investigated. The Ω3-epoxides, like the EETs, are metabolized by the soluble epoxide hydrolase to corresponding diols and epoxide hydrolase inhibition increases epoxide levels and demonstrates anti-hypertensive as well as anti-inflammatory effects. It seems that the overall consequences of CYP epoxygenase activation largely depend on enzyme substrate preference and the endogenous Ω-3/Ω-6 PUFA ratio. This review outlines the evidence for a physiological role for EETs in the regulation of vascular homeostasis.
More Related Videos
Related Concept Videos
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Regulation of Angiogenesis and Blood Supply
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Cholesterol: Significance and Regulation
Considering cholesterol and...
IP3/DAG Signaling Pathway
Atherosclerosis III: Management

